patents.google.com

IS7400A - Cathepsin cysteine protease inhibitor - Google Patents

️Thu Aug 12 2004

IS7400A - Cathepsin cysteine protease inhibitor - Google Patents

Cathepsin cysteine protease inhibitor

Info

Publication number

IS7400A

IS7400A IS7400A IS7400A IS7400A IS 7400 A IS7400 A IS 7400A IS 7400 A IS7400 A IS 7400A IS 7400 A IS7400 A IS 7400A IS 7400 A IS7400 A IS 7400A Authority

Iceland

Prior art keywords

cysteine protease

protease inhibitor

cathepsin cysteine

compounds

cathepsin

Prior art date

2002-03-05

Application number

IS7400A

Other languages

Icelandic (is)

Other versions

IS2549B (en

Inventor

I. Bayly Christopher

Black Cameron

Leger Serge

Sing Li Chun

Mckay Dan

Mellon Christopher

Yves Gauthier Jacques

Lau Cheuk

Therien Michel

Truong Vouy-Linh

J. Green Michael

L. Hirschbein Bernard

W. Janc James

T. Palmer James

Baskaran Chitra

Original Assignee

Merck Frosst Canada Ltd.

Axyx Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-05

Filing date

2004-08-12

Publication date

2004-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27807943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-12 Application filed by Merck Frosst Canada Ltd., Axyx Pharmaceuticals, Inc. filed Critical Merck Frosst Canada Ltd.

2004-08-12 Publication of IS7400A publication Critical patent/IS7400A/en

2009-10-15 Publication of IS2549B publication Critical patent/IS2549B/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/17—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and doubly-bound oxygen atoms bound to the same acyclic carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/25—Aminoacetonitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Quinoline Compounds (AREA)
Epoxy Compounds (AREA)

Abstract

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

IS7400A 2002-03-05 2004-08-12 Cathepsin cysteine protease inhibitor IS2549B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36181802P	2002-03-05	2002-03-05
US40870402P	2002-09-06	2002-09-06
PCT/US2003/006147 WO2003075836A2 (en)	2002-03-05	2003-02-28	Cathepsin cysteine protease inhibitors

Publications (2)

Publication Number	Publication Date
IS7400A true IS7400A (en)	2004-08-12
IS2549B IS2549B (en)	2009-10-15

Family

ID=27807943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7400A IS2549B (en)	2002-03-05	2004-08-12	Cathepsin cysteine protease inhibitor

Country Status (28)

Country	Link
US (6)	US7375134B2 (en)
EP (1)	EP1482924B1 (en)
JP (2)	JP4201716B2 (en)
KR (1)	KR100975784B1 (en)
CN (1)	CN100430052C (en)
AT (1)	ATE395911T1 (en)
AU (1)	AU2003219953B8 (en)
BR (1)	BRPI0308208B8 (en)
CA (1)	CA2477657C (en)
CL (1)	CL2003001743A1 (en)
CY (1)	CY1111130T1 (en)
DE (1)	DE60321141D1 (en)
DK (1)	DK1482924T3 (en)
EC (1)	ECSP045261A (en)
ES (1)	ES2305452T3 (en)
HK (1)	HK1080375A1 (en)
HR (1)	HRP20040800B1 (en)
IL (2)	IL163748A0 (en)
IS (1)	IS2549B (en)
MA (1)	MA27295A1 (en)
MX (1)	MXPA04008621A (en)
NO (1)	NO335099B1 (en)
NZ (1)	NZ534583A (en)
PL (1)	PL215865B1 (en)
PT (1)	PT1482924E (en)
RU (1)	RU2312861C2 (en)
SI (1)	SI1482924T1 (en)
WO (1)	WO2003075836A2 (en)

Families Citing this family (123)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
US9937531B2 (en)	2009-03-10	2018-04-10	Bookit Oy Ajanvarauspalvelu	Method and system for delivery of goods
JP4865989B2 (en)	2002-02-01	2012-02-01	ベンド・リサーチ・インコーポレーテッド	Method for producing a homogeneous spray-dried solid amorphous drug dispersion using an improved spray-drying apparatus
US7375134B2 (en) *	2002-03-05	2008-05-20	Axys Pharmaceuticals, Inc.	Cathepsin cysteine protease inhibitors
JPWO2003077948A1 (en) *	2002-03-19	2005-07-14	興和株式会社	Myeloma tumor preventive / therapeutic agent and diagnostic method thereof
CN1809536A (en) *	2003-04-24	2006-07-26	麦克公司	Inhibitors of Akt activity
JP4553899B2 (en) *	2003-08-21	2010-09-29	メルクフロストカナダリミテツド	Cathepsin cysteine protease inhibitor
EP1660436A4 (en) *	2003-08-27	2006-11-22	Merck Frosst Canada Ltd	Cathepsin inhibitors
US7547701B2 (en) *	2003-09-18	2009-06-16	Virobay, Inc.	Haloalkyl containing compounds as cysteine protease inhibitors
WO2005040142A1 (en)	2003-10-24	2005-05-06	Aventis Pharmaceuticals Inc.	Novel keto-oxadiazole derivatives as cathepsin inhibitors
CA2548600A1 (en) *	2003-12-12	2005-06-23	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
AU2005203820A1 (en) *	2004-01-08	2005-07-21	Merck Frosst Canada Ltd	Cathepsin cysteine protease inhibitors
US7429674B2 (en)	2004-04-14	2008-09-30	Merck & Co. Inc..	Process for preparing fluoroleucine alkyl esters
JP4769802B2 (en) *	2004-08-04	2011-09-07	メルク・シャープ・エンド・ドーム・コーポレイション	Method of diastereoselective reductive amination
EP1799645A2 (en) *	2004-09-17	2007-06-27	Bayer Schering Pharma Aktiengesellschaft	Processes and intermediates for preparing cysteine protease inhibitors
TW200619206A (en) *	2004-09-29	2006-06-16	Anormed Inc	Chemokine-binding heterocyclic compound salts, and methods of use thereof
AR055283A1 (en) *	2004-11-23	2007-08-15	Merck Frosst Canada Ltd	CATEPSIN CISTEINPROTEASE INHIBITORS
JP4988589B2 (en) *	2004-12-01	2012-08-01	ビロベイ，インコーポレイティド	Haloalkyl-containing compounds as cysteine protease inhibitors
WO2006060810A1 (en)	2004-12-02	2006-06-08	Schering Aktiengesellschaft	Sulfonamide compounds as cysteine protease inhibitors
EP1841730A4 (en) *	2005-01-19	2010-10-27	Merck Frosst Canada Ltd	Cathepsin k inhibitors and atherosclerosis
EP1841419A4 (en) *	2005-01-19	2009-02-25	Merck Frosst Canada Ltd	Cathepsin k inhibitors and obesity
WO2006093467A1 (en) *	2005-03-02	2006-09-08	Agency For Science, Technology And Research	Conjugated organic molecules for molecular electronic devices
JP2008531691A (en) *	2005-03-02	2008-08-14	メルクエンドカムパニーインコーポレーテッド	Cathepsin K inhibitory composition
DK1865940T3 (en)	2005-03-21	2013-03-04	Virobay Inc	ALPHAKETOAMIDE COMPOUNDS AS CYSTEIN PROTEASE INHIBITORS
EP1866277B1 (en) *	2005-03-22	2014-06-25	Virobay, Inc.	Sulfonyl containing compounds as cysteine protease inhibitors
EP1891003A4 (en)	2005-06-02	2010-07-21	Merck Frosst Canada Ltd	Fluoroalkylamine derivatives as cathepsin inhibitors
TWI371272B (en)	2005-07-19	2012-09-01	Sankyo Co	Substituted propanamide derivatives and pharmaceutical compositions thereof
WO2007012180A1 (en) *	2005-07-26	2007-02-01	Merck Frosst Canada Ltd.	Papain family cysteine protease inhibitors for the treatment of parasitic diseases
JP5312320B2 (en) *	2006-06-01	2013-10-09	サノフイ	Spirocyclic nitriles as protease inhibitors
US7622593B2 (en) *	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
KR101486763B1 (en)	2006-10-04	2015-01-28	비로베이, 인코포레이티드	Difluoro containing compounds as cysteine protease inhibitors
US7893112B2 (en)	2006-10-04	2011-02-22	Virobay, Inc.	Di-fluoro containing compounds as cysteine protease inhibitors
WO2008080969A1 (en) *	2006-12-29	2008-07-10	Abbott Gmbh & Co. Kg	Carboxamide compounds and their use as calpain inhibitors
US20090318560A1 (en)	2007-02-26	2009-12-24	Wayne Parent	Formulations for cathepsin k inhibitors
JP5364695B2 (en) *	2007-04-02	2013-12-11	メルクカナダインコーポレイテッド	Method for preparing amidation of cathepsin K inhibitor
KR20100023948A (en)	2007-06-08	2010-03-04	닛뽕 케미파 가부시키가이샤	Therapeutic or prophylactic agent for cerebral aneurysm
JPWO2009054454A1 (en)	2007-10-24	2011-03-03	国立大学法人東京医科歯科大学	Modulator of signal transduction of Toll-like receptor containing cathepsin inhibitor as an active ingredient
CA2706746C (en) *	2007-11-29	2016-02-23	Merck Frosst Canada Ltd.	Cysteine protease inhibitors for the treatment of parasitic diseases
WO2009096198A1 (en) *	2008-02-01	2009-08-06	Pharma Ip Limited Liability Intermediary Corporations	Novel biaryl derivative
BRPI0822420A2 (en) *	2008-04-01	2014-10-07	Virobay Inc	COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A DISEASE IN AN ANIMAL AND TO TREAT A PATIENT WHO GOES THROUGH A TAREPIA.
US20090291945A1 (en) *	2008-04-09	2009-11-26	Teijin Pharma Limited	Cysteine protease inhibitors
EP2291079B1 (en) *	2008-05-14	2013-04-24	Merck Sharp & Dohme Corp.	Formulations for cathepsin k inhibitors
JP5518997B2 (en) *	2009-04-20	2014-06-11	エフ．ホフマン−ラロシュアーゲー	Proline derivatives as cathepsin inhibitors
US8324417B2 (en) *	2009-08-19	2012-12-04	Virobay, Inc.	Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US9051304B2 (en) *	2009-12-22	2015-06-09	AbbVie Deutschland GmbH & Co. KG	Carboxamide compounds and their use as calpain inhibitors V
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8791162B2 (en)	2011-02-14	2014-07-29	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
EP2681188A4 (en) *	2011-03-02	2015-04-15	Merck Sharp & Dohme	AMIDATION METHOD
US8680152B2 (en)	2011-05-02	2014-03-25	Virobay, Inc.	Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
SG194842A1 (en)	2011-05-16	2013-12-30	Bayer Ip Gmbh	Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
JP6158833B2 (en)	2012-01-09	2017-07-05	アローヘッドファーマシューティカルズインコーポレイテッド	Organic composition for treating beta-catenin related diseases
LT3176170T (en)	2012-06-13	2019-04-25	Incyte Holdings Corporation	Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9528011B2 (en)	2013-01-11	2016-12-27	Ceraloc Innovation Ab	Digital binder and powder print
RS57106B1 (en)	2013-02-19	2018-06-29	Novartis Ag	Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
PE20160122A1 (en)	2013-03-13	2016-02-12	Forma Therapeutics Inc	NOBLE COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
MX393494B (en)	2013-04-19	2025-03-24	Incyte Holdings Corp	BICYCLIC HETEROCYCLES AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTORS (FGFR).
US20160106679A1 (en)	2013-05-16	2016-04-21	Sandoz Ag	Tablet with increased drug load of odanacatib
EP2808012A1 (en)	2013-05-29	2014-12-03	ratiopharm GmbH	Method for producing dosage form comprising odanacatib
JP6336973B2 (en)	2013-06-14	2018-06-06	生化学工業株式会社	α-Oxoacylaminocaprolactam derivatives
JP6226437B2 (en)	2013-06-14	2017-11-08	生化学工業株式会社	α-Oxoacylaminocaprolactam
EP3019468A4 (en) *	2013-07-11	2017-01-11	Merck Sharp & Dohme Corp.	Formulations for cathepsin k inhibitors with vitamin d
RU2692799C2 (en) *	2013-10-08	2019-06-27	Мерк Шарп И Доум Корп.	Cathepsin cysteine protease inhibitors
WO2015092634A1 (en)	2013-12-16	2015-06-25	Novartis Ag	1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
EP3094629B1 (en)	2014-01-17	2018-08-22	Novartis AG	1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (en)	2014-01-17	2020-07-05	Novartis Ag	N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
CN105899491B (en)	2014-01-17	2019-04-02	诺华股份有限公司	For inhibiting the active 1- pyridazine-of SHP2/triazine -3- base-piperazine (- piperazine)/pyridine/pyrrolidin derivatives and combinations thereof
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CZ2014941A3 (en)	2014-12-19	2016-06-29	Zentiva, K.S.	Preparation process of extremely pure intermediate for odanacatib synthesis
MA51229A (en)	2015-02-20	2021-03-24	Incyte Corp	BICYCLIC HETEROCYCLES USED AS FGFR INHIBITORS
MA41551A (en)	2015-02-20	2017-12-26	Incyte Corp	BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
CA2976766A1 (en)	2015-03-25	2016-09-29	Novartis Ag	Formylated n-heterocyclic derivatives as fgfr4 inhibitors
ES2741746T3 (en)	2015-06-19	2020-02-12	Novartis Ag	Compounds and compositions to inhibit SHP2 activity
JP6718889B2 (en)	2015-06-19	2020-07-08	ノバルティスアーゲー	Compounds and compositions for inhibiting the activity of SHP2
EP3310771B1 (en)	2015-06-19	2020-07-22	Novartis AG	Compounds and compositions for inhibiting the activity of shp2
EP3342765B1 (en) *	2015-08-29	2021-09-15	Sunshine Lake Pharma Co., Ltd.	Cathepsin k inhibitor and application thereof
JP2019500330A (en) *	2015-11-26	2019-01-10	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Trypanosoma inhibitor
CN106866502B (en) *	2015-12-10	2020-10-09	广东东阳光药业有限公司	Cathepsin K inhibitors and uses thereof
US10577362B2 (en)	2016-05-04	2020-03-03	Genoscience Pharma	Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
CN109415360B (en)	2016-06-14	2021-11-02	诺华股份有限公司	Compounds and compositions for inhibiting SHP2 activity
UA124036C2 (en) *	2017-01-24	2021-07-07	Астеллас Фарма Інк.	PHENYL DIFLUORTHOMETHYL SUBSTITUTED COMPOUND OF PROLINAMIDE
KR101916396B1 (en)	2017-02-20	2018-11-08	서울대학교 산학협력단	Protease inhibitor being used as anti-tumor agent or anti-microbial agent
AR111960A1 (en)	2017-05-26	2019-09-04	Incyte Corp	CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
MA50245A (en)	2017-09-11	2020-07-22	Krouzon Pharmaceuticals Inc	OCTAHYDROCYCLOPENTA ALLOSTERIC INHIBITORS [C] SHP2 PYRROLE
NL2020021B1 (en) *	2017-12-05	2019-06-13	Academisch Ziekenhuis Leiden	Cathepsin inhibitors
EP4046987A1 (en) *	2017-12-05	2022-08-24	Academisch Ziekenhuis Leiden (h.o.d.n. LUMC)	Cathepsin inhibitors
KR102709682B1 (en)	2018-03-28	2024-09-25	한림제약(주)	2-cyanopyrimidin-4-yl carbamate or urea derivative or its salt and pharmaceutical composition comprising the same
EA202092649A1 (en)	2018-05-04	2021-06-21	Инсайт Корпорейшн	FGFR INHIBITOR SALTS
TWI870349B (en)	2018-05-04	2025-01-21	美商英塞特公司	Solid forms of an fgfr inhibitor and processes for preparing the same
MX2021003158A (en)	2018-09-18	2021-07-16	Nikang Therapeutics Inc	Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors.
EP3856349A1 (en)	2018-09-25	2021-08-04	Black Diamond Therapeutics, Inc.	Tyrosine kinase inhibitor compositions, methods of making and methods of use
CA3113241A1 (en)	2018-09-25	2020-04-02	Black Diamond Therapeutics, Inc.	Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
US12138262B2 (en)	2018-09-29	2024-11-12	Novartis Ag	Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition
TWI767148B (en)	2018-10-10	2022-06-11	美商弗瑪治療公司	Inhibiting fatty acid synthase (fasn)
WO2020092395A1 (en)	2018-10-29	2020-05-07	Forma Therapeutics, Inc.	SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
US20220193048A1 (en)	2019-04-05	2022-06-23	Universite De Bretagne Occidentale	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021030711A1 (en)	2019-08-15	2021-02-18	Black Diamond Therapeutics, Inc.	Alkynyl quinazoline compounds
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN115835908A (en)	2019-10-14	2023-03-21	因赛特公司	Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP2023505257A (en)	2019-12-04	2023-02-08	インサイト・コーポレイション	Derivatives of FGFR inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021195206A1 (en)	2020-03-24	2021-09-30	Black Diamond Therapeutics, Inc.	Polymorphic forms and related uses
EP4204020A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
WO2022043557A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
WO2022043556A1 (en)	2020-08-31	2022-03-03	Novartis Ag	Stable radiopharmaceutical composition
CN114539111A (en) *	2020-11-19	2022-05-27	深圳信立泰药业股份有限公司	Salt of odancate and its preparation method and medical use
WO2022140472A1 (en)	2020-12-22	2022-06-30	Nikang Therapeutics, Inc.	Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
JP2024504932A (en)	2021-01-13	2024-02-02	モンテローザセラピューティクス，インコーポレイテッド	isoindolinone compound
WO2022170052A1 (en)	2021-02-05	2022-08-11	Black Diamond Therapeutics, Inc.	Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
EP4323350A1 (en)	2021-04-14	2024-02-21	Monte Rosa Therapeutics AG	Isoindolinone compounds
WO2022219412A1 (en)	2021-04-14	2022-10-20	Monte Rosa Therapeutics Ag	Isoindolinone amide compounds useful to treat diseases associated with gspt1
AR126102A1 (en)	2021-06-09	2023-09-13	Incyte Corp	TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP4370522A1 (en)	2021-07-14	2024-05-22	Nikang Therapeutics, Inc.	Alkylidene derivatives as kras inhibitors
US20230303509A1 (en)	2022-03-28	2023-09-28	Nikang Therapeutics, Inc.	Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
CN119790053A (en)	2022-06-08	2025-04-08	霖康疗法公司	Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors
TW202434563A (en)	2022-11-11	2024-09-01	美商尼坎醫療公司	Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025072462A1 (en)	2023-09-27	2025-04-03	Nikang Therapeutics, Inc.	Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
DE69841871D1 (en) *	1997-11-05	2010-10-14	Novartis Ag	Dipeptide nitrile
WO2000049007A1 (en) *	1999-02-20	2000-08-24	Astrazeneca Ab	Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
IL145430A0 (en) *	1999-03-15	2002-06-30	Axys Pharm Inc	N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
EP1212302A1 (en) *	1999-09-16	2002-06-12	Axys Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions as cathepsin s inhibitors
GB0003111D0 (en) *	2000-02-10	2000-03-29	Novartis Ag	Organic compounds
EP1283825B1 (en) *	2000-05-15	2005-09-14	Novartis AG	N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
CA2439415C (en) *	2001-03-02	2011-09-20	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
WO2003017598A1 (en) *	2001-08-15	2003-02-27	The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations	Scsi-to-ip cache storage device and method
EP1446115B1 (en) *	2001-11-13	2008-02-27	Merck Frosst Canada Ltd.	Cyanoalkylamino derivatives as protease inhibitors
US7375134B2 (en)	2002-03-05	2008-05-20	Axys Pharmaceuticals, Inc.	Cathepsin cysteine protease inhibitors
US7547701B2 (en) *	2003-09-18	2009-06-16	Virobay, Inc.	Haloalkyl containing compounds as cysteine protease inhibitors
AR055283A1 (en) *	2004-11-23	2007-08-15	Merck Frosst Canada Ltd	CATEPSIN CISTEINPROTEASE INHIBITORS
EP1891003A4 (en) *	2005-06-02	2010-07-21	Merck Frosst Canada Ltd	Fluoroalkylamine derivatives as cathepsin inhibitors

2003
- 2003-02-28 US US10/505,796 patent/US7375134B2/en not_active Expired - Lifetime
- 2003-02-28 CN CNB038051818A patent/CN100430052C/en not_active Expired - Fee Related
- 2003-02-28 PT PT03716238T patent/PT1482924E/en unknown
- 2003-02-28 EP EP03716238A patent/EP1482924B1/en not_active Expired - Lifetime
- 2003-02-28 PL PL372204A patent/PL215865B1/en unknown
- 2003-02-28 IL IL16374803A patent/IL163748A0/en unknown
- 2003-02-28 ES ES03716238T patent/ES2305452T3/en not_active Expired - Lifetime
- 2003-02-28 US US10/377,377 patent/US20030232863A1/en not_active Abandoned
- 2003-02-28 KR KR1020047013833A patent/KR100975784B1/en not_active Expired - Fee Related
- 2003-02-28 NZ NZ534583A patent/NZ534583A/en not_active IP Right Cessation
- 2003-02-28 AT AT03716238T patent/ATE395911T1/en active
- 2003-02-28 RU RU2004129587/04A patent/RU2312861C2/en active
- 2003-02-28 CA CA2477657A patent/CA2477657C/en not_active Expired - Lifetime
- 2003-02-28 JP JP2003574112A patent/JP4201716B2/en not_active Expired - Fee Related
- 2003-02-28 SI SI200331271T patent/SI1482924T1/en unknown
- 2003-02-28 DK DK03716238T patent/DK1482924T3/en active
- 2003-02-28 MX MXPA04008621A patent/MXPA04008621A/en active IP Right Grant
- 2003-02-28 BR BRPI0308208A patent/BRPI0308208B8/en not_active IP Right Cessation
- 2003-02-28 AU AU2003219953A patent/AU2003219953B8/en not_active Ceased
- 2003-02-28 WO PCT/US2003/006147 patent/WO2003075836A2/en active Application Filing
- 2003-02-28 DE DE60321141T patent/DE60321141D1/en not_active Expired - Lifetime
- 2003-08-27 CL CL200301743A patent/CL2003001743A1/en unknown
2004
- 2004-08-12 IS IS7400A patent/IS2549B/en unknown
- 2004-08-17 MA MA27826A patent/MA27295A1/en unknown
- 2004-08-26 IL IL163748A patent/IL163748A/en not_active IP Right Cessation
- 2004-09-01 EC EC2004005261A patent/ECSP045261A/en unknown
- 2004-09-03 HR HR20040800 patent/HRP20040800B1/en not_active IP Right Cessation
- 2004-10-04 NO NO20044207A patent/NO335099B1/en not_active IP Right Cessation
2006
- 2006-01-10 HK HK06100394.6A patent/HK1080375A1/en not_active IP Right Cessation
2007
- 2007-10-31 JP JP2007283678A patent/JP4918456B2/en not_active Expired - Fee Related
2008
- 2008-04-08 US US12/082,104 patent/US7973037B2/en not_active Expired - Lifetime
- 2008-08-19 CY CY20081100883T patent/CY1111130T1/en unknown
2011
- 2011-05-25 US US13/115,462 patent/US8318748B2/en not_active Expired - Fee Related
2012
- 2012-10-11 US US13/649,670 patent/US8772336B2/en not_active Expired - Lifetime
2014
- 2014-05-20 US US14/282,395 patent/US20140256743A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1482924T3 (en)	2008-09-29
IL163748A (en)	2013-10-31
KR20040095262A (en)	2004-11-12
US20030232863A1 (en)	2003-12-18
NO20044207L (en)	2004-11-24
CA2477657A1 (en)	2003-09-18
KR100975784B1 (en)	2010-08-17
AU2003219953A1 (en)	2003-09-22
RU2312861C2 (en)	2007-12-20
JP2008115177A (en)	2008-05-22
RU2004129587A (en)	2005-05-10
HRP20040800B1 (en)	2012-11-30
US20140256743A1 (en)	2014-09-11
BR0308208A (en)	2005-01-11
CL2003001743A1 (en)	2005-05-06
WO2003075836A2 (en)	2003-09-18
BRPI0308208B1 (en)	2017-04-18
IS2549B (en)	2009-10-15
SI1482924T1 (en)	2008-12-31
PL215865B1 (en)	2014-02-28
CN100430052C (en)	2008-11-05
BRPI0308208B8 (en)	2021-05-25
HK1080375A1 (en)	2006-04-28
CN1638757A (en)	2005-07-13
US20110230446A1 (en)	2011-09-22
MA27295A1 (en)	2005-05-02
CY1111130T1 (en)	2015-06-11
AU2003219953B2 (en)	2007-11-01
WO2003075836A3 (en)	2004-07-15
CA2477657C (en)	2011-04-26
JP4201716B2 (en)	2008-12-24
EP1482924A4 (en)	2006-03-08
US8772336B2 (en)	2014-07-08
MXPA04008621A (en)	2004-12-06
AU2003219953B8 (en)	2008-09-25
US7375134B2 (en)	2008-05-20
NO335099B1 (en)	2014-09-15
ECSP045261A (en)	2004-10-26
EP1482924B1 (en)	2008-05-21
US20130035312A1 (en)	2013-02-07
DE60321141D1 (en)	2008-07-03
PL372204A1 (en)	2005-07-11
US7973037B2 (en)	2011-07-05
US20080188529A1 (en)	2008-08-07
NZ534583A (en)	2006-11-30
JP2005526753A (en)	2005-09-08
US8318748B2 (en)	2012-11-27
EP1482924A2 (en)	2004-12-08
JP4918456B2 (en)	2012-04-18
US20050240023A1 (en)	2005-10-27
IL163748A0 (en)	2005-12-18
ATE395911T1 (en)	2008-06-15
HRP20040800A2 (en)	2005-04-30
PT1482924E (en)	2008-08-27
ES2305452T3 (en)	2008-11-01

Publication	Publication Date	Title
IS7400A (en)	2004-08-12	Cathepsin cysteine protease inhibitor
ATE409482T1 (en)	2008-10-15	CATHEPSINCYSTEIN PROTEASE INHIBITORS
TW200631576A (en)	2006-09-16	Cathepsin cysteine protease inhibitors
EP1902031A4 (en)	2009-09-16	Cathepsin cysteine protease inhibitors
PT1423391E (en)	2006-09-29	PYROLOPYRIMIDINES AS AGENTS FOR INHIBITION OF CYSTEINE PROTEASES
SE0201976D0 (en)	2002-06-24	Novel compounds
ATE443043T1 (en)	2009-10-15	PHENYLCARBOXAMIDE AS A BETA-SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S
NO20061627L (en)	2006-04-10	Haloalkyl containing compounds as cysteine protease inhibitors
CY1107342T1 (en)	2012-12-19	USE OF NITRIL PRODUCERS AS MEDICINE
ATE423122T1 (en)	2009-03-15	CONDENSED HETEROCYCLES AS INHIBITORS OF GLUTAMATRACEMASE (MURI)
TNSN06138A1 (en)	2007-11-15	INHIBITORS OF THE MUTANT FORM OF KIT
TW200700057A (en)	2007-01-01	Alpha ketoamide compounds as cysteine protease inhibitors
AR021241A1 (en)	2002-07-03	PROTEASE INHIBITORS
WO2002070517A3 (en)	2003-01-16	Cathepsin cysteine protease inhibitors
WO2001034565A3 (en)	2001-10-04	Protease inhibitors
WO2005063742A3 (en)	2005-08-18	Amidino compounds as cysteine protease inhibitors
WO2001034566A3 (en)	2003-07-31	Protease inhibitors
MY139221A (en)	2009-08-28	Cathepsin cysteine protease inhibitors
DE50210473D1 (en)	2007-08-23	PHOSPHINATE PEPTIDE ANALOGUE AS INHIBITORS OF PROCOLLAGEN C PROTEINASE (PCP) FOR THE TREATMENT OF FIBROTIC DISEASES
DOP2005000240A (en)	2006-06-15	CATEPSIN CISTEINE PROTEASES INHIBITORS
ECSP993018A (en)	1999-11-29	NEW PROTEASE INHIBITORS, PARTICULARLY CYSTEINE AND SERINE PROTEASE INHIBITORS
ECSP993211A (en)	2000-01-27	PROTEASE INHIBITORS VI
TH85776A (en)	2007-08-10	Cathetersin cystine protease inhibitor

IS7400A - Cathepsin cysteine protease inhibitor - Google Patents